February 25, 2005
Researchers Defend Alert
Researchers on Thursday defended their decision to notify city officials and alert the public about the case as a potentially serious health threat, the New York Times reports. Some scientists and gay rights advocates have criticized the public health alert as "premature and unnecessarily alarmist," according to the Times (Altman/Santora, New York Times, 2/25). Advocates also are concerned that highlighting the case could create a "backlash" against men who have sex with men, Reuters reports (Fox, Reuters, 2/24). However, alerting the city health department was "the right thing to do," Ho said, adding that scientists remain unsure about whether the case is isolated or "part of a cluster," according to the Times. "That is a decision we stand by today," he said. "I think we have a unique convergence of a very drug-resistant virus, and this infection was very, very rapid," Ho said, adding, "And this man has many, many sexual partners." Ho also reported that his team has not found any of the key genetic indicators that might explain the man's rapid progression to AIDS. He said testing is ongoing but warned that even after all of the testing is complete, "there will still be room for doubt" because the knowledge about genetic markers is "incomplete," according to the Times (New York Times, 2/25).
Doctors on Thursday also presented evidence and discussed "an array of disturbing traits" of the HIV strain, the AP/Las Vegas Sun reports. "The unique feature of this case is the convergence of ... the transmission of a remarkably drug-resistant HIV-1 variant and the extremely rapid clinical course to AIDS," the New York City patient's physicians said. The virus is able to use both main entry points to infect cells and grows well in laboratory settings, unlike most drug-resistant strains, according to the AP/Sun. In addition, the virus causes infected cells to clump together, allowing them to more easily attack healthy cells (Donn, AP/Las Vegas Sun, 2/24). HIV penetrates cells through both the CCR5 and CXCR4 portals, a capability that is linked to "aggressive" progression to AIDS, the Wall Street Journal reports. Ho and Martin Markowitz, also of ADARC, said that the strain retains "some sensitivity" to two drugs: enfuvirtide, sold as Fuzeon, and efavirenz, sold as Sustiva. Ho added that the man is being treated with a combination of "a huge number of drugs" (Chase, Wall Street Journal, 2/25).
"The investigation is ongoing and will most likely continue for many weeks," Lucia Torian, New York's director of HIV surveillance and epidemiology, said. New York City Health Commissioner Thomas Frieden plans to send letters to six commercial labs and several smaller labs that conduct most of the country's HIV testing to ask that they report to his department all samples of multidrug-resistant HIV strains taken from city residents, according to Torian. The order is scheduled to run through May 31 and could be extended, she said (Washington Post, 2/25). Ho said that the New York City man had unprotected sex with more than 100 men in the months before his diagnosis, the Daily News reports (New York Daily News, 2/25). Frieden said the city "has been working to identify (the man's) sexual partners and urge them to be tested," the New York Post reports (Edozien, New York Post, 2/25). The New York City patient has given health department investigators the names of his known sexual partners -- a number "in the teens," according to Torian -- and officials have contacted about two-thirds of them, according to the Washington Post. Investigators are asking that the men undergo HIV testing and to be tested for drug resistance if they test positive. Torian would not provide results from any of the testing conducted thus far, according to the Washington Post (Washington Post, 2/25).
Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2004 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.